Personalized Medicine in HFpEF

Why is biological phenotyping needed to improve current clinical treatment of heart failure with preserved ejection fraction (HFpEF)? Listen as Guest Editor Maria Bloksgaard (University of Southern Denmark) interviews lead author Vanessa van Empel (Maastricht University Medical Centre) and content expert Nicholas Houstis (Massachusetts General Hospital) about the new Review by Barandiarán Aizpurua et al, which points out that if we want to develop more personalized HFpEF treatments, we need greater understanding of the underlying pathophysiology of HFpEF. Can animal models of HFpEF “match” clinical phenotypes and accurately mimic exercise intolerance, congestive heart failure, and cardiovascular death experienced by HFpEF patients? Listen now and find out.

 

Arantxa Barandiarán Aizpurua, Blanche Schroen, Marc van Bilsen, and Vanessa P. M. van Empel Targeted HFpEF therapy based on matchmaking of human and animal models Am J Physiol Heart Circ Physiol, published September 21, 2018. DOI: 10.1152/ajpheart.00024.2018